Literature DB >> 2151487

Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models.

J E Leggett1, S Ebert, B Fantin, W A Craig.   

Abstract

Relatively few animal studies have investigated the influence of dosing regimens on the efficacy of antibiotics possessing different pharmacodynamic characteristics. We evaluated the impact of dosing interval on the relative efficacy and potency of beta-lactams, aminoglycosides, and ciprofloxacin against Pseudomonas aeruginosa. Escherichia coli, and Klebsiella pneumoniae in murine pneumonitis and thigh-infection models. We used a sigmoid dose-response model to determine the maximal bactericidal effect at 24 hours (Emax) and the total dose required to achieve 50% of Emax (P50) at several dosing intervals. P50S (a measure of drug potency, in mg/kg/day) for beta-lactams increased 14- to 73-fold with longer intervals in both models. Dosing interval had little impact on P50S for aminoglycosides or ciprofloxacin. Emax varied among drugs but displayed no dependence on dosing interval. This method of analysis allows comparison of efficacy and dependence of potency on dosing regimen among different classes of antibiotics.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2151487

Source DB:  PubMed          Journal:  Scand J Infect Dis Suppl        ISSN: 0300-8878


  34 in total

1.  Pharmacodynamics of S-3578, a novel cephem, in murine lung and systemic infection models.

Authors:  Shuichi Miyazaki; Kenichi Okazaki; Masakatsu Tsuji; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

2.  Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of danofloxacin in sheep biological fluids.

Authors:  F Shojaee Aliabadi; M F Landoni; P Lees
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

3.  Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141.

Authors:  Johan W Mouton; Anne Schmitt-Hoffmann; Stuart Shapiro; Norman Nashed; Nieko C Punt
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 4.  Continuous infusion of beta-lactam antibiotics.

Authors:  W A Craig; S C Ebert
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

5.  Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.

Authors:  Jürgen B Bulitta; Martina Kinzig; Verena Jakob; Ulrike Holzgrabe; Fritz Sörgel; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

6.  Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection.

Authors:  David M Rothstein; Ronald S Farquhar; Klari Sirokman; Karen L Sondergaard; Charles Hazlett; Angelia A Doye; Judith K Gwathmey; Steve Mullin; John van Duzer; Christopher K Murphy
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

7.  Novel bacterial NAD+-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy in vivo.

Authors:  Scott D Mills; Ann E Eakin; Ed T Buurman; Joseph V Newman; Ning Gao; Hoan Huynh; Kenneth D Johnson; Sushmita Lahiri; Adam B Shapiro; Grant K Walkup; Wei Yang; Suzanne S Stokes
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

8.  Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection.

Authors:  Irma A J M Bakker-Woudenberg; Marian T ten Kate; Wil H F Goessens; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

9.  Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.

Authors:  Thomas P Lodise; Ben Lomaestro; Keith A Rodvold; Larry H Danziger; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

10.  Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia.

Authors:  S Daenen; Z Erjavec; D R Uges; H G De Vries-Hospers; P De Jonge; M R Halie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.